Thomas John Charles sold KRYS

Source

Document

SEC Form 4

Publisher

U.S. Securities and Exchange Commission (EDGAR)

Document ID

0002114900-26-000009

Machine-readable

Structured copy

Timestamps

Event (reported)

Jun 25, 2026

Published

Jun 26, 2026

Ingested by INSIDER

Nov 5, 03:50 UTC

Last re-read

Nov 5, 03:50 UTC

Extracted facts

Filer

Thomas John Charles

Role

EVP, General Counsel

Transaction

Open-market saleAs filed: “S”

Asset

Krystal Biotech, Inc.

Ticker

KRYS

Shares

1,000

Price per share

$347.27

Value

$347,270

Execution date (reported)

Jun 25, 2026

Owned after transaction

0 shares

Rule 10b5-1 plan

Yes, as checked by the filer

Days from execution to publication

1

Calculation

What this establishes

Thomas John Charles filed this Form 4 reporting a open-market sale of KRYS on Jun 25, 2026. It became public on Jun 26, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

Extraction

Method

Form 4 XML

Confidence

1.00

EVP, General Counsel

Thomas John Charlescik:0002114900

Issuer

Krystal Biotech, Inc.cik:0001711279

Revision history · 0

No field has changed since this record was first ingested.